Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 10/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3785819 | 0.94 | P2RX7 (0.44) | P2RX7KMT2AMEN1POLBHDAC6 | |
| SCHEMBL3759804 | 0.91 | HDAC6 (0.48) | P2RX7POLBHDAC6SMN1; SMN2HTT | |
| SCHEMBL3755499 | 0.90 | P2RX7 (0.41) | P2RX7KMT2APOLBHDAC6SMN1; SMN2 | |
| SCHEMBL3759965 | 0.88 | P2RX7 (0.45) | P2RX7KMT2AGLASMN1; SMN2LMNA | |
| SCHEMBL3761284 | 0.87 | HTT (0.58) | KMT2AMEN1SMN1; SMN2HTTLMNA | |
| SCHEMBL3759959 | 0.87 | P2RX7 (0.41) | P2RX7KMT2AGLASMN1; SMN2LMNA | |
| SCHEMBL3762001 | 0.85 | KMT2A (0.50) | P2RX7KMT2AMEN1HDAC6GLA | |
| SCHEMBL3760532 | 0.84 | ALDH1A1 (0.57) | P2RX7KMT2AMEN1HTTLMNA | |
| SCHEMBL3757585 | 0.83 | P2RX7 (0.47) | P2RX7KMT2AMEN1HDAC6GLA | |
| SCHEMBL3759996 | 0.82 | HTT (0.44) | KMT2AMEN1SMN1; SMN2HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962639-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2015-02-24 | — | — | US | claimed |
| WO-2010138828-A2 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | claimed |
| US-20100305109-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | claimed |
| US-8962639-B2 | Potassium channel modulators | ABBVIE INC. (US) | 2015-02-24 | — | — | US | disclosed |
| WO-2010138828-A2 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305109-A1 | POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305109-A1 | POTASSIUM CHANNEL MODULATORS | KCNQ1, KCNQ2, KCNJ2 | P2RX7 172/4885KMT2A 642/4885MEN1 1599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.